# Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC

> **NCT06699498** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 45 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Neoadjuvant Therapy
- PD-L1
- Anlotinib

## Interventions

- **DRUG:** Benmelstobart
- **DRUG:** Anlotinib
- **DRUG:** Cisplatin
- **DRUG:** Paclitaxel for Injection （Albumin Bound）

## Key facts

- **NCT ID:** NCT06699498
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-03
- **Primary completion:** 2025-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06699498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06699498, "Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06699498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*